The future of biomedical innovation depends in part on a new trend for all players in biomedical innovation to work together for the common goal, say 2 MIT researchers
It’s a long, expensive, risky road to turn a scientific breakthrough into a treatment that can help patients. Fewer organizations are trying to tackle the challenges alone, says a new paper from MIT researchers published August 28 in the journal Science Translational Medicine.
An essential new way to move discoveries forward has emerged in the form of multi-stakeholder collaborations involving three or more different types of organizations, such as drug companies, government regulators and patient groups, write Magdalini Papadaki, a research associate, and Gigi Hirsch, a physician-entrepreneur and executive director of the MIT Center for Biomedical Innovation.
The authors are calling for a new “science of collaboration” to learn what works and doesn’t work; to improve how leaders can design, manage and evaluate collaborations; and to help educate and train future leaders with the necessary organizational and managerial skills.
“Getting new, better, affordable drugs to the right patients faster involves a series of historically independent decisions made by different players or stakeholders,” says Hirsch. The system is uncoordinated, takes too long, and costs too much. In some cases, the drug—such as new antibiotics for life-threatening resistant infections—may never become available.
“One of the interesting paradoxes of biomedical innovation is increasingly going to be that even though we have the scientific knowledge required to provide potentially better treatments for patients—or even to prevent disease in those who are at high risk—we may be unable to help patients benefit from them anytime soon,” she says.
To help change this scenario, in the last decade, thousands of researchers, pharmaceutical and biotechnology companies, government regulators, payers, clinicians and patients have come together in more than 100 multi-stakeholder collaborations to solve some specific shared problem standing in the way of finding a cure or a better diagnostic approach.
“Multi-stakeholder collaborations provide the opportunity to create an environment that allows for new kinds of interactions among the players,” Hirsch says. The largest multi-stakeholder effort, the European Union’s Innovative Medicines Initiative (IMI) began in 2008 and has established more than 40 consortia with financial and in-kind investments totaling €2 billion. Some projects focus on specific health issues, such as Alzheimer’s disease, chronic pain, diabetes and obesity. Others tackle bigger issues, such as drug and vaccine safety and the use of stem cells for drug discovery. The success has led to a proposal to extend the effort for 10 years and €3.5 billion. Last year, the U.S. President’s Council of Advisors on Science and Technology (PCAST) recommended the U.S. form something similar.
“The prevalence of multi-stakeholder initiatives reflects a continued optimism about the value of this collaboration approach for addressing biomedical innovation bottlenecks,” the authors write in the paper. “Although the need for collaboration is no longer in question, it is worth noting the importance of this development. A willingness to share proprietary data among industry competitors represents a dramatic shift in the culture of the historically highly competitive pharmaceutical industry.”
The article reviews the history of collaborations beginning with HIV/AIDS. By the early 2000s, multi-stakeholder collaborations proliferated to address the need for important tools, such as biomarkers, that require preclinical data sharing. Since then, they have reached to encompass later stages in product development, including manufacturing, reimbursement and post-market monitoring.
Some people involved in multi-stakeholder consortia are concerned about redundancy, inefficiency and lack of productivity of some collaborative efforts, all contributing to a sense of “consortium fatigue,” the researchers write.
In a newer trend, funders and participants are seeking a smaller number of strategically coordinated initiatives that will reliably address critical gaps, Hirsch and Papadaki write. They cite the example of TransCelerate BioPharma, a group of 10 major pharmaceutical companies that came together to share and direct resources toward selected priorities in order to improve the efficiency of drug development, such as clinical trial site qualification standards.
The authors propose a rigorous evidence-based approach (the science of collaboration) to figure out what works and doesn’t work in collaborations. They recommend early steps in this new field and structuring the research to help learn from the past but also to evolve effectively as new innovation challenges emerge.
The Latest on: Science of collaboration
- Aspire Academy, Bulgarian minister discuss prospects of collaborationon January 12, 2020 at 4:00 pm
Tribune News NetworkDohaAspire Academy welcomed a high-ranking delegation from Bulgaria led by Minister of Education and Science Krasimir Georgiev Valchev on Sunday.During the visit, Aspire Academy’s ...
- University of St. Augustine for Health Sciences Celebrates Five Years of Offering ImPACT Applications' Credential Programson January 11, 2020 at 7:10 am
SAN DIEGO, Jan. 11, 2020 /PRNewswire-PRWeb/ -- The University of St. Augustine for Health Sciences celebrates five years of providing education focused on concussion care and rehab in partnership with ...
- Concerto HealthAI Announces Expanded Collaboration with Pfizer to Accelerate Real-World Evidence and AI Technologies for Additional Disease Areason January 10, 2020 at 4:21 pm
The collaboration, first announced in early 2019 ... Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent.
- The Future of the U.S. and China: Collaboration & Competitionon January 10, 2020 at 12:27 pm
Yuen Yuen Ang - Associate Professor of Political Science, University of Michigan - Yuen Yuen Ang is a political scientist ... Michael has led McKinsey research in such areas as data & analytics, ...
- McGill researchers honored in Québec Science 2019 list of top discoverieson January 10, 2020 at 6:37 am
Research from McGill University topped Québec Science's annual list of the 10 most important scientific breakthroughs ... Their research offers a new method for tracking the status of free-flowing ...
- Collaboration receives $1.25m to accelerate development of effective topical drugson January 10, 2020 at 2:09 am
“The successful attainment of this objective will advance regulatory science and accelerate the route-to-market of new drug products.” Stimulated Raman spectroscopy. (Courtesy: NPL) NPL will provide ...
- Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeuticson January 9, 2020 at 6:06 am
During the three-year collaboration, Empirico will utilize its Precision Insights Platform ... About Empirico Empirico is a next-generation therapeutics company founded on utilizing human genetics, ...
- ADDING MULTIMEDIA Sleep Number Announces Collaboration With Mayo Clinic to Advance Sleep Science and Cardiovascular Medicineon January 8, 2020 at 9:04 am
In collaboration with Mayo Clinic, Sleep Number will advance sleep science and products that will have meaningful impact on society, linking sleep to personal wellness. As a purpose-driven company, ...
- Sleep Number Announces Collaboration With Mayo Clinic to Advance Sleep Science and Cardiovascular Medicineon January 8, 2020 at 6:55 am
In collaboration with Mayo Clinic, Sleep Number will advance sleep science and products that will have meaningful impact on society, linking sleep to personal wellness. About Sleep Number As a purpose ...
- Grower citizen science project uses collaboration to improve soil healthon January 6, 2020 at 11:00 am
The primary goal of the project to identify practices that increase soil health. The Grower Citizen Science Project is a collaboration between soil scientists and growers in the southern High Plains ...
via Google News and Bing News